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Background: CD8þ T lymphocytes in the peripheral airways have been suggested to be involved
in the pathogenesis of COPD. However, the significance of CD8þ T lymphocyte activation in
COPD is not well understood. A biomarker of CD8þ T lymphocyte activation in patients with
COPD is required.
Methods: Thirty COPD patients and twenty-one healthy controls (eleven ex-smokers and ten
who had never smoked or were light ex-smokers) were included in this study. We separately
obtained epithelial lining fluid (ELF) from central and peripheral airways using a bronchoscopic
microsampling technique. Levels of perforin in ELF were measured and we examined correla-
tions between its values and patients characteristics including pulmonary function.
Results: Perforin levels in both the central and peripheral airways in COPD patients were
significantly higher than those in the healthy control groups. In the healthy control groups,
there was no significant difference in perforin levels between central and peripheral airways.
However, in COPD patients, perforin levels in peripheral airways were significantly higher than
those in central airways. Perforin levels in peripheral airways were significantly correlated
with FEV1 (percent predicted), FEV1/FVC, and DLco (percent predicted) in COPD patients.
Conclusion: The microsampling technique is safe and useful for separately obtaining ELF from
central and peripheral airways. Levels of perforin in ELF from peripheral airways were signif-
icantly increased and correlated with the degree of pulmonary dysfunction. Perforin might
reflect inflammation involving CD8þ T-lymphocytes. This novel biomarker might enable better
understanding of the pathogenesis of COPD.
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1886 N. Shiratsuchi et al.Introduction epithelial lining fluid (ELF) samples separately obtainedChronic obstructive pulmonary disease (COPD) is a major
worldwide health problem that has exhibited increasing
prevalence and mortality. The prevalence, morbidity, and
mortality of COPD vary appreciably across countries, but in
general are directly related to the prevalence of cigarette
smoking. COPD is characterized by airflow limitation that is
not fully reversible, usually progressive, and associated
with abnormal inflammatory responses of the lung. Indeed,
one important pathological feature of COPD is chronic
inflammation characterized by an influx of inflammatory
cells in the lumen and wall of the bronchial and bronchiolar
airways and parenchyma.1,2 In this respect, there are
strong correlations between lung function, airway wall
area, the degree of luminal occlusion, and the degree of
inflammatory infiltrates in the airways of patients with
COPD.1 However, several studies using surgically resected
lung tissue, autopsy lung specimens, and transbronchial
biopsies have indicated that more severe inflammatory and
structural changes occur in the small airways of COPD.1,3
Thus, the airflow limitation in COPD probably occurs as
a result of small airways inflammation.
There is accumulating evidence that CD8þ T lympho-
cytes play an important role in the initiation and progres-
sion of COPD. In particular, a previous study reported that
the number of CD8þ T lymphocytes in COPD lungs was
directly related to the degree of airflow limitation.4 More-
over, a close correlation was found between emphysema
assessed by CT and the number of tissue CD8þ T lympho-
cytes in the lungs.5 These findings suggest the direct
pathophysiological importance of these cells in the decline
of lung function in COPD. The presumed role of CD8þ T
lymphocytes was suggested by histopathologic studies that
found associations between disease severity and the extent
of CD8þ T lymphocyte infiltrates within airways of patients
with COPD. Since these previous methods are highly inva-
sive, a less invasive biomarker of CD8þ T lymphocyte acti-
vation in patients with COPD is required for wide used in
clinical investigations.
CD8þ T lymphocytes are believed to lead to chronic
inflammation by releasing various inflammatory mediators
such as interferon (IFN)-g, tumor necrosis factor (TNF)-a, as
well as perforin.6 Perforin is about 70kD protein and stored
in secretory granules of CD8þ T lymphocytes as a monomer.
Perforin is released near target cells and it polymerizes to
form transmembrane pores in those cells in the presence of
Ca2þ. Then granzyme which also stored in secretory gran-
ules of CD8þ T lymphocytes enters target cells and leads to
apoptosis. It was previously reported that the percentages
of T-cells expressing intracellular perforin in bron-
choalveolar lavage fluid (BALF) in both former and current
smokers with COPD were increased compared to those in
individuals who had never smoked.7 Chrysofakis et al. also
reported that perforin expression by CD8þ lymphocytes in
induced sputum was significantly higher in smokers with
COPD than in those without COPD and healthy non-
smokers.8 These findings suggest that perforin expression
may be enhanced in airways of COPD. However, no studies
have evaluated the soluble form of perforin in the airways
of patients with COPD. We have already established
a method of measurement of biochemical constituents infrom the central or peripheral airways using a broncho-
scopic microsampling technique.9 Using this method, we
attempted to measure the concentrations of the soluble
form of perforin in ELF in central or peripheral airways
separately, and determined whether its levels were corre-




Thirty COPD patients and twenty-one control subjects from
the outpatient clinic of our hospital were enrolled in this
study. They underwent bronchoscopy to identify the cause
of small peripheral nodules. Subjects who agreed to
undergo ELF sampling were randomly selected for inclusion
in this study. All COPD patients were ex-smokers, and
satisfied the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria for the diagnosis of COPD. They had
been free of acute upper respiratory tract infections, and
none had received inhaled bronchodilators or corticoste-
roids. Control subjects were divided into two groups based
on smoking history (eleven subjects were ex-smokers and
ten who had never smoked or were light ex-smokers with
less than a five-pack-year history). In this study, we defined
the latter group as non-smokers. All ex-smokers had quit
smoking at least one year before entering this study.
Pulmonary function tests including the diffusing capacity of
the lung for carbon monoxide (DLco) were performed in all
subjects. In all study subjects, chest computed tomo-
graphic scans revealed no abnormal diffuse interstitial
infiltrates, and results of arterial blood gas analyses were
normal. All subjects gave written informed consent for
participation in the study, which was approved by the
Ethics Committee of Osaka City University.
Bronchoscopic microsampling technique
ELF was obtained using a previously described broncho-
scopic microsampling technique.9 In brief, after premed-
ication of the subject with atropine and pentazocine, and
administration of local anesthesia with aerosolized lido-
caine hydrochloride, a flexible fiberoptic bronchoscope (BF-
240, Olympus, Tokyo, Japan) was inserted in the trachea
and, after flushing with air to minimize contamination of
the samples, advanced into the target bronchus. Subse-
quently, a microsampling probe (BC-402C, Olympus, Tokyo,
Japan) was then inserted through the channel of the
bronchoscope. The probe consists of a 2.5 mm outer-
diameter polyethylene sheath and a 1.9 mm inner poly-
ester fiber rod probe attached to a stainless steel guide
wire. Bronchial microsampling was performed in all
subjects from a second bronchus (central airway sample).
Next, a thin flexible fiberoptic bronchoscope (BF-P260F,
Olympus, Tokyo, Japan) was inserted into the lung, and the
microsampling probe (BC-401C, Olympus, Tokyo, Japan)
was then inserted through the channel of the broncho-
scope. This probe consists of a 1.8 mm outer-diameter
polyethylene sheath and a 1.1 mm inner polyester fiber
Figure 1 Comparison of perforin levels in epithelial lining
fluid in central airway and peripheral airway ( central airway,
peripheral airway).
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bronchioles under direct vision using this thin bronchofiber
scope in the same subjects (peripheral airway sample). ELF
was collected in each subject from a lung field contralat-
eral to the small peripheral nodules. The inner probe was
advanced into the bronchial lumen slowly for 15 s to avoid
injuring the bronchial wall. The inner probe was then
withdrawn into the outer tube, and the two were with-
drawn together to avoid contamination. The same proce-
dure was repeated three times. Then the inner probe was
cut 3 cm distal from its tip, and the wet probe was frozen at
80 C freezer until use. Diluted solution for measurements
of biochemical constituents was prepared by adding 1 ml of
saline to the tube containing the frozen probe and vortexed
for 1 min. The probe was dried and weighed to measure the
ELF volume recovered, and the dilution factor was
calculated.
Measurement of biochemical constituents in ELF
Using the ELF samples processed as described above, the
concentration of soluble perforin was measured by enzyme-
linked immunosorbent assay (ELISA) (Mabtech AB, Sweden).
The assay kits for perforin have a 36 pg/ml detection limit,
using antiserum that has 100% reactivity with perforin.
Statistical analysis
All values are presented as the median [range]. Compari-
sons between the COPD group and two healthy controls
were performed using the KruskaleWallis test. When the
comparisons were significant, nonparametric analyses of
variance with the Bonferroni/Dunn’s post hoc test were
performed. Comparisons between perforin levels in
peripheral and central airways in each group were per-
formed with the Wilcoxon matched-pairs signed-rank test.
The significances of correlations were determined by
calculation of Spearman’s rank correlation coefficients. For
all tests, findings of p < 0.05 were considered significant.
Results
The clinical characteristics of the 10 non-smokers, 11 ex-
smokers, and 30 COPD patients are shown in Table 1. The
three groups were well matched for gender and age.Table 1 Clinical characteristics of study subjects.
Non-smokers
Subject No. (male/female) 10 (8/2)
Age (yr) 68 (6.5)
Smoking history (pack-years) 0.37 (0.60)
FEV1 (% predicted) 97 (14)
FEV1/FVC (%) 79 (3.8)
DLco (% predicted) 107 (18)
All values are presented as mean (SD). Difinition of abbreviations:FEV
capacity, DLco Z diffusing capacity for carbon monoxide.
**p < 0.01 compared with non-smokers.
*p < 0.05 compared with non-smokers.
#p < 0.01 compared with ex-smokers.Moreover, smoking index was the same in ex-smokers and
COPD patients, though FEV1, FEV1/FVC, and DLco were
significantly lower in COPD patients. In addition, DLco was
also significantly lower in ex-smokers than in non-smokers.
For all study subjects, we could successfully perform our
bronchoscopic microsampling technique. Furthermore, this
method had no detrimental effects on oxygenation during
the procedure nor did it affect baseline lung function.
Perforin levels in ELF in neither central nor peripheral
airways significantly differed between non-smokers and ex-
smokers (non-smokers: median [range], central 0 [0e38]
pg/mL, peripheral 2.5 [0e43] pg/mL; ex-smokers: central
36 [0e138] pg/mL, peripheral 58 [0-144] pg/mL) (Fig. 1).
However, those levels were significantly higher in COPD
patients than in non-smokers and ex-smokers (COPD
patients: central 99 [0e252] pg/mL, p < 0.01 for non-
smokers, p Z 0.02 for ex-smokers, peripheral 182 [0e368]
pg/mL, p < 0.01 for non-smokers, p < 0.01 for ex-smokers).
Moreover, in non-smokers and ex-smokers, perforin levels
in ELF did not differ significantly between central and
peripheral airways. However, in COPD patients these levels
were significantly higher in peripheral airways. On the
other hand, there were no significant correlations between
smoking indices and perforin levels in either central or
peripheral airways in COPD patients (Fig. 2).
In COPD patients, we evaluated the correlations between
perforin levels in the central or peripheral airways andEx-smokers COPD patients
11 (10/1) 30 (26/4)
65 (13) 68 (11)
52 (23)** 56 (35)**
93 (7.6) 65 (9.8)**#
76 (3.5) 54 (8.9)**#
91 (11)* 67 (17)**#
1 Z forced expiratory volume in one second, FVC Z forced vital
Figure 2 Correlation between perforin levels and smoking index in COPD patients.
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perforin levels in central airways were correlated with the
degree of airflow obstruction (Fig. 3, Fig. 4) and the decline
of DLco (Fig. 5). Moreover, perforin level in peripheral
airways was closely correlated with FEV1 (r Z 0.37,
p Z 0.04), FEV1/FVC (r Z 0.47, p Z 0.01), and DLco
(r Z 0.66, p < 0.01).Figure 3 Correlation between perforinDiscussion
We successfully measured the concentration of the soluble
form of perforin in ELF samples in central and peripheral
airways in human subjects, and our microsampling tech-
nique was found to be very safe without any complications.
Using our method, we found that (1) perforin levels in ELFlevels and %FEV1 in COPD patients.
Figure 4 Correlation between perforin levels and FEV1/FVC(%) in COPD patients.
Soluble perforin in COPD 1889in both central and peripheral airways were significantly
higher in COPD patients than in non-smokers and ex-
smokers, (2) these levels in peripheral airways of COPD
patients were closely correlated with FEV1, FEV1/FVC, and
DLco. The number of CD8þ T lymphocytes in the airways is
known to be increased in COPD patients compared with
control subjects.4 Since perforin is strongly expressed in
activated CD8þ T lymphocytes, it is plausible that soluble
perforin levels in ELF reflect the number of activated CD8þ
T lymphocytes that have infiltrated in the airways. Actually,
concerning the magnitude of perforin expression in CD8þ T
lymphocytes from induced sputum and BALF, perforinFigure 5 Correlation between perforinexpression was significantly increased in COPD.7,8 These
findings thus suggest that CD8þ T lymphocytes infiltrate
into both central and peripheral airway walls in COPD
patients. Moreover, as peripheral airways inflammation has
attracted much recent attention, separate observation in
central and peripheral airways will be needed. In this
regard, since we selectively obtained ELF from the seventh
or eighth bronchioles using a thin bronchoscope with a thin
probe as peripheral airways, our analysis of ELF samples
from peripheral airways is considered to reflect peripheral
airways inflammation. In this study, we demonstrated that
perforin levels in the peripheral airways were significantlylevels and %DLco in COPD patients.
1890 N. Shiratsuchi et al.higher than those in the central airways in COPD patients.
Activated CD8þ T lymphocytes might thus be increased in
peripheral airways of COPD patients. It is known that
magnitude of inflammation is higher in peripheral airways
in COPD patients. Proinflammatory cytokines in small
airways of COPD might activate CD8þ T lymphocytes and
up-regulate the expression of perforin in these cells.
We found significant correlation between perforin levels
in peripheral airways and the degree of airflow obstruction
in COPD patients. The so-called peripheral airways consist
of small bronchioles and are subject to airway narrowing by
either inflammatory process such as thickening of airway
walls or following airway remodeling. Hogg et al. previously
reported an inverse correlation between the severity of
inflammation in small airways and FEV1 over the full range
of COPD severity.2 These findings suggest that higher levels
of perforin in peripheral airways are associated with
increased severity of airflow limitation in COPD patients.
Decreases in DLco in COPD patients usually reflect the
destruction of pulmonary parenchyma. In COPD airways,
CD8þ T lymphocytes infiltrate and initiate apoptosis of lung
constitutive cells by co-releasing perforin and granzyme B.
In the alveolar region, apoptosis might induce loss of
alveolar walls leading to emphysema.10 Thus, perforin in
peripheral airways might be involved in the pathogenesis of
COPD apoptosis. In this study perforin levels in central
airways of COPD patients were not closely correlated with
the degree of pulmonary function. However, we could see
trends that those levels in central airways were correlated
with such parameters. This lack of correlation might be due
to a relatively small number of samples. The fact that
perforin levels in central airways were significantly higher
in COPD patients than in non-smokers and ex-smokers
indicates activated CD8þ T lymphocytes might be
increased in central airways as in peripheral airways. The
number of activated CD8þ T lymphocytes in peripheral
airways may be more increased than in central airways.
Exposure to noxious gas such as cigarette smoke is the
main cause of COPD. There is some evidence regarding the
relationship between cigarette smoke exposure and CD8þ
T-cell activation.11 Cigarette smoke exposure might affect
the expression of perforin in COPD airways via CD8þ T
lymphocyte activation. However, no correlations were
found between smoking indices and the perforin levels in
either central or peripheral airways in COPD patients in this
study. This indicates that the influence of smoking on the
degree of CD8þ T lymphocyte activation in increasing per-
forin expression differs in each patient. It is known that,
only ten to fifteen percent of smokers develop COPD. This
difference in susceptibility to COPD is believed to be
related to hereditary factors.12 The result of this study
suggests that the diversity in degree of CD8þ T lymphocyte
activation in response to cigarette smoke exposure might
be one of those factors. In addition, perforin levels in ELF in
neither central nor peripheral airways significantly differed
between non-smokers and ex-smokers. There are two
possible explanations of this result. One is that in ex-
smokers, airway inflammation might not occur from the
very beginning. Another is that airway inflammation is
sustained during smoking but subsides after smoking
cessation. Genetic variation might exist in whether the
inflammation in airways is prolonged or not once initiatedby smoking. Perhaps prolongation of chronic inflammation
leads to COPD. The levels of perforin in peripheral airways
may be predictive factor for risk of COPD.
In this study, we separately measured perforin levels in
central and peripheral airways and found increased levels
of perforin in peripheral airways of COPD patients. The
microsampling technique is less invasive and more repeat-
able than bronchial biopsy, and repeated sampling such as
pre- and post-therapeutic intervention will aid determina-
tion of the dynamics of CD8þ T-lymphocytes in the patho-
genesis of COPD. Moreover, the result using epithelial lining
fluid to observe airways might be replaced with induced
sputum which is less invasive and more repeatable.
Increased levels of perforin in peripheral airways might be
an important feature of airway inflammation of COPD, and
perforin has the potential for use as a novel biomarker for
better understanding of the pathogenesis of COPD. Further
examinations addressing the potential of perforin and its
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